Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model: A comparative study with captopril

Circulation

Volumn 93, Issue 2, 1996, Pages 333-339

  Furukawa, Yutaka ^a   Matsumori, Akira ^a   Hirozane, Toshiro ^a   Sasayama, Shigetake ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

angiotensin; coronary disease; receptors; rejection; transplantation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTERY WALL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HISTOLOGY; LAPAROTOMY; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECIPIENT;

EID: 0030070654     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.2.333     Document Type: Article

References (46)

1. Bieber CP, Hunt SA, Schwinn DA, Jamieson SA, Reitz BA, Oyer PE, Shumway NE, Stinson EB. Complication in long-term survivors of cardiac transplantation. Transplant Proc. 1981;13:207-211.
2. Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc. 1987;19(suppl 5):19-25.
3. Uretsky BF, Murali S, Reddy PS, Rabin B, Lee A, Griffith BP, Hardesty RL, Trento A, Bahnson HT. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 1987;76:827-834.
4. Gao SZ, Schroeder JS, Alderman EL, Hunt SA, Silverman JF, Wiederhold V, Stinson EB. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation. 1987;76(suppl V):V-56-V-61.
5. Gao SZ, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol. 1988; 12:334-340.
6. Billingham ME. Graft coronary artery disease: the lesions and the patients. Transplant Proc. 1989;21:3665-3666.
7. Gao SZ, Schroeder JS, Hunt S, Stinson EB. Retransplantation for severe accelerated coronary artery disease in heart transplant recipients. Am J Cardiol. 1988;62:876-881.
8. Ensley RD, Hunt S, Taylor DO, Renlund DG, Menlove RL, Karwande SV, O'Connell JB, Barr ML, Michler RE, Copeland JG, Miller LW. Predictors of survival after repeat heart transplantation: the Registry of the International Society for Heart and Lung Transplantation, and Contributing Investigators. J Heart Lung Transplant. 1992;11:S142-S158.
9. Re RN. The cellular biology of angiotensin: paracrine, autocrine and intracrine actions in cardiovascular tissues. J Mol Cell Cardiol. 1989;21(suppl V):63-69.
10. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension. 1991;18(suppl II):II-100-II-105.
11. Dzau VJ. Vascular renin-angiotensin system and vascular protection. J Cardiovasc Pharmacol. 1993;22(suppl 5):S1-S9.
12. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83: 1419-1424.
13. 1 expression determines growth response to angiotensin II. J Clin Invest. 1992;90:456-461.
14. Berk BC, Rao GN. Angiotensin Il-induced vascular smooth muscle cell hypertrophy: PDGF A-chain mediates the increase in cell size. J Cell Physiol. 1993;154:368-380.
15. Hahn AWA, Resink TJ, Kern F, Bühler FR. Peptide vasoconstrictors, vessel structure, and vascular smooth-muscle proliferation. J Cardiovasc Pharmacol. 1993;22(suppl 5):S37-S43.
16. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245:186-188.
17. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Anti-atherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327-331.
18. Rolland PH, Charpiot P, Friggi A, Piquet P, Barlatier A, Scalbert E, Bodard H, Tranier P, Mercier C, Luccioni R, Garcon D. Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure, and wall rheology in the hind-quarters of atherosclerotic mini-pigs. Am J Cardiol. 1993;71: 22E-27E.
19. Kobayashi J, Crawford SE, Backer CL, Zales VR, Takami H, Hsueh C, Huang L, Mavroudis C. Captopril reduces graft coronary artery disease in a rat heterotopic transplant model. Circulation. 1993;88(part 2):286-290.
20. Schrör K. Converting-enzyme inhibitors and the interaction between kinins and eicosanoids. J Cardiovasc Pharmacol. 1990; 15(suppl 6):S60-S68.
21. Farhy RD, Carretero OA, Ho KL, Guillermo S. Role of kinins and nitric oxide in the effects of angiotensin-converting enzyme inhibitors on neointima formation. Circ Res. 1993;72:1202-1210.
22. Busse R, Fleming I, Hecker M. Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy. J Cardiovasc Pharmacol. 1993;22(suppl 5):S31-S36.
23. Hirozane T, Matsumori A, Furukawa Y, Sasayama S. Experimental graft coronary artery disease in a murine heterotopic cardiac transplant model. Circulation. 1995;91:386-392.
24. Corry RJ, Winn HJ, Russel PS. Primary vascularized allografts of hearts in mice. Transplantation. 1973;16:344-350.
25. Tanaka A, Matsumori A, Wang W, Sasayama S. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. Circulation. 1994;90:2051-2055.
26. Suzuki H, Matsumori A, Matoba Y, Kyu BS, Tanaka A, Fujita J, Sasayama S. Enhanced expression of superoxide dismutase messenger RNA in viral myocarditis: an SH-dependent reduction of its expression and myocardial injury. J Clin Invest. 1993;91:2727-2733.
27. Kojima M, Shiojima I, Yamazaki T, Komuro I, Yunzeng Z, Ying W, Mizuno T, Ueki K, Tobe K, Kadowaki T, Nagai R, Yazaki Y. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation. 1994;89:2204-2211.
28. Chodera A, Feller K. Some aspects of pharmacokinetic and biotransformation differences in humans and mammal animals. Int J Clin Pharmacol Biopharm. 1978;16:357-360.
29. Adams DH, Tilney NL, Collins JJ Jr, Karnovsky MJ. Experimental graft arteriosclerosis, I: the Lewis-to-F-344 allograft model. Transplantation. 1992;53:1115-1119.
30. Alonso DR, Sorek PK, Minick R. Studies on the pathogenesis of atherosclerosis induced in rabbit cardiac allografts by synergy of graft rejection and hypercholesterolemia. Am J Pathol 1977;87: 415-433.
31. Lurie KG, Billingham ME, Jamieson SW, Harrison DC, Reitz BA. Pathogenesis and prevention of graft atherosclerosis in an experimental heart transplant model. Transplantation. 1981;31:41-47.
32. Nobuyoshi M, Kimura T, Ohishi H, Horiuchi H, Nosaka H, Hamasaki N, Yokoi H, Kim K. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol. 1991;17:433-439.
33. Miller MJ, Kuntz RE, Friedrich SP, Leidig GA, Fishman RF, Schnitt SJ, Baim DS, Safian RD. Frequency and consequences of intimai hyperplasia in specimens retrieved by directional atherectomy of native primary coronary artery stenoses and subsequent restenoses. Am J Cardiol. 1993;71:652-658.
34. Paul LC, Fellstrom B. Chronic vascular rejection of the heart and the kidney: have rational treatment options emerged? Transplantation. 1992;53:1169-1179.
35. Soulillou JP. Cytokines and transplantation. Transplant Proc. 1993; 25:106-108.
36. Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
37. Kawamura M, Terashita Z, Okuda H, Imura Y, Shino A, Nakao M, Nishikawa K. TCV-116, a novel angiotensin II receptor antagonist, prevents intimai thickening and impairment of vascular function after carotid injury in rats. J Pharmacol Exp Ther. 1993;266: 1664-1669.
38. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husam A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265: 22348-22357.
39. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993;91: 1269-1281.
40. The Multicenter European Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin-converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR Study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation. 1992;86:100-110.
41. Desmet W, Vrolix M, Scheerder ID, Lierde JV, Willems JL, Piessens J. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Circulation. 1994;89:385-392.
42. Deflraissy JF, Galanaud P, Balavoine JF, Wallon C, Dormont J. Captopril and immune regulation. Kidney Int. 1984;25:925-929.
43. Weinstock JV, Blum AM, Kassab JT. Angiotensin II is chemotactic for a T-cell subset which can express migration factor activity in murine schistosomiasis mansoni. Cell Immunol. 1987;107:180-187.
44. Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann WH. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation. 1993;88:2849-2861.
45. Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, Baker KM. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Cirr Res. 1993;72:1245-1254.
46. 1, receptor subtype. Circ Res. 1993;73:413-423.